P2Y₁₂, A New Platelet ADP Receptor, Target of Clopidogrel

 

 Buy Article Permissions and Reprints

ABSTRACT

Clopidogrel is a potent antithrombotic drug that inhibits ADP-induced platelet aggregation. The results of large clinical trials have demonstrated an overall benefit of clopidogrel over aspirin in the prevention of vascular ischemic events (myocardial infarction, stroke, vascular death) in patients with a history of symptomatic atherosclerotic disease. The antiaggregating effect of clopidogrel is attributed to an irreversible inhibition of ADP binding to a purinergic receptor present at the platelet surface. Clopidogrel is not active in vitro and can be considered a precursor of an active metabolite formed in the liver. The chemical structure of this active metabolite and its biological activity have been described recently. Several purinergic receptors have been described on platelets; P2X₁, a calcium channel, and P2Y1 a Gq-coupled seven-transmembrane domain receptor, have been found not to be antagonized by clopidogrel. Another Gi₂-coupled receptor (named P2Y12) has been recently cloned and stably expressed in CHO cells. These cells displayed a strong affinity for ³³P-2MeS-ADP, a stable analogue of ADP, the binding characteristics of which corresponded in all points to those observed on platelets. The binding of ³³P-2MeS-ADP to these cells was strongly inhibited by the active metabolite of clopidogrel with a potency that was consistent with that observed for this compound on platelets. In these transfected CHO cells, as in platelets, ADP and 2MeS-ADP induced adenylyl cyclase downregulation, an effect that was inhibited by the active metabolite of clopidogrel. These results demonstrate that this receptor corresponds to the previously called “P2t” platelet receptor and show that the active metabolite of clopidogrel binds in a covalent manner to this receptor, thus explaining how it blocks the aggregating effect of ADP on platelets.

REFERENCES

• 1 Anti-platelet Trialists Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet therapy.  Br Med J . 1988;  296 320-331
  PubMedGoogle Scholar
• 2 Hass W K, Easton J D, Adams Jr P H, Pryse-Phillips W, Molony B A, Anderson S. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group.  N Engl J Med . 1989;  321 501-507
  CrossrefPubMedGoogle Scholar
• 3 Gent M, Blakely J A, Easton J D. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke.  Lancet . 1989;  1 1215-1220
  PubMedGoogle Scholar
• 4 Janzon L, Bergqvist D, Boberg J. Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicenter Study.  J Intern Med . 1990;  227 301-308
  CrossrefPubMedGoogle Scholar
• 5 CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE).  Lancet . 1996;  348 1329-1339
  CrossrefPubMedGoogle Scholar
• 6 CURE Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.  N Engl J Med . 2001;  345 494-502
  CrossrefPubMedGoogle Scholar
• 7 Herbert J M, Frehel D, Vallée E. Clopidogrel, a novel antiplatelet and antithrombotic agent.  Cardiovasc Drug Rev . 1993;  11 180-198
  CrossrefPubMedGoogle Scholar
• 8 Panak E, Maffrand J P, Picard-Fraire C, Vallée E, Blanchard J, Roncucci R. Ticlopidine: a promise for the prevention and treatment of thrombosis and its complications.  Haemostasis . 1983;  13 1-54
  PubMedGoogle Scholar
• 9 Herbert J M, Bernat A, Maffrand J P. Importance of platelets in experimental venous thrombosis in the rat.  Blood . 1992;  80 2281-2286
  PubMedGoogle Scholar
• 10 Hérault J P, Dol F, Gaich C, Bernat A, Herbert J M. Effect of clopidogrel on thrombin generation in platelet rich plasma in the rat.  Thromb Haemost . 1999;  81 957-960
  PubMedGoogle Scholar
• 11 Savi P, Bernat A, Dumas A, Ait-Chek L, Herbert J M. Effect of aspirin and clopidogrel on platelet-dependent tissue factor expression in endothelial cells.  Thromb Res . 1994;  73 117-124
  CrossrefPubMedGoogle Scholar
• 12 Mazoyer E, Ripoll L, Boisseau M R, Drouet L. How does ticlopidine treatment lower plasma fibrinogen?.  Thromb Res . 1994;  75 361-370
  CrossrefPubMedGoogle Scholar
• 13 Hayakawa M, Kuzuya F. Effects of ticlopidine on erythrocyte aggregation in thrombotic disorders.  Angiology . 1991;  42 747-753
  PubMedGoogle Scholar
• 14 de Lorgeril M, Bordet J C, Salen P, Durbin S, Defreyn G, Delaye J, Boissonnat P. Ticlopidine increases nitric oxide generation in heart-transplant recipients: a possible novel property of ticlopidine.  J Cardiovasc Pharmacol . 1998;  32 225-230
  CrossrefPubMedGoogle Scholar
• 15 Cimminiello C, Milani M, Uberti T, Arpaia G, Bonfardeci G. Effects of ticlopidine and indobufen on platelet aggregation induced by A23187 and adrenaline in the presence of different anticoagulants.  J Int Med Res . 1989;  17 514-520
  PubMedGoogle Scholar
• 16 Ashida S I, Abiko Y. Mode of action of ticlopidine in inhibition of platelet aggregation in the rat.  Thromb Haemost . 1979;  41 436-449
  PubMedGoogle Scholar
• 17 Bonne C, Battais E. Ticlopidine and adenylate cyclase.  Agents Actions . 1984;  15 88-96
  PubMedGoogle Scholar
• 18 Gachet C, Stierlé A, Cazenave J P, Ohlmann P, Lanza F, Bouloux C, Maffrand J P. The thienopyridine PCR 4099 selectively inhibits ADP-induced platelet aggregation and fibrinogen binding without modifying the membrane glycoprotein IIb-IIIa complex in rat and in man.  Biochem Pharmacol . 1990;  40 229-238
  CrossrefPubMedGoogle Scholar
• 19 Johnson M, Heywood J B. Possible mode of action of ticlopidine: a novel inhibitor of platelet aggregation.  Thromb Haemost . 1979;  42 367
  PubMedGoogle Scholar
• 20 Gachet C, Cazenave J P, Ohlmann P, Bouloux C, Defreyn G, Driot F, Maffrand J P. The thienopyridine ticlopidine selectively prevents the inhibitory effects of ADP but not of adrenaline on cAMP levels raised by stimulation of the adenylate cyclase of human platelets by PGE1.  Biochem Pharmacol . 1990;  40 2683-2687
  CrossrefPubMedGoogle Scholar
• 21 Defreyn G, Gachet C, Savi P, Driot F, Cazenave J P, Maffrand J P. Ticlopidine and clopidogrel (SR 25990C) selectively neutralize ADP inhibition of PGE1-activated platelet adenylate cyclase in rats and rabbits.  Thromb Haemost . 1991;  65 186-190
  PubMedGoogle Scholar
• 22 Cattaneo M, Akkawat B, Lecchi A, Cimminiello C, Capitanio A M, Mannucci P M. Ticlopidine selectively inhibits human platelet responses to adenosine diphosphate.  Thromb Haemost . 1991;  66 694-699
  PubMedGoogle Scholar
• 23 Weber A A, Reimann S, Schror K. Specific inhibition of ADP-induced platelet aggregation by clopidogrel in vitro.  Br J Pharmacol . 1999;  126 415-420
  CrossrefPubMedGoogle Scholar
• 24 Abou-Khalil S, Abou-Khalil W H, Yunis A A. Mechanism of interaction of ticlopidine and its analogues with the energy-conserving mechanism in mitochondria.  Biochem Pharmacol . 1986;  35 1855-1859
  CrossrefPubMedGoogle Scholar
• 25 Klein-Soyer C, Cazenave J P, Herbert J M, Maffrand J P. SR 25989 inhibits healing of a mechanical wound of confluent human saphenous vein endothelial cells which is modulated by standard heparin and growth factors.  J Cell Physiol . 1994;  160 316-322
  CrossrefPubMedGoogle Scholar
• 26 Chen W H, Yin H L, Chang Y Y, Lan M Y, Hsu H Y, Liu J S. Antiplatelet drugs induce apoptosis in cultured cancer cells.  Kaohsiung J Med Sci . 1997;  13 589-597
  PubMedGoogle Scholar
• 27 Maffrand J P, Defreyn G, Bernat A, Delebassée D, Tissinier A M. Reviewed pharmacology of ticlopidine.  Act Med Int Angiol . 1988;  (suppl)77 6-13
  PubMedGoogle Scholar
• 28 Savi P, Herbert J M, Pflieger A M. Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel.  Biochem Pharmacol . 1992;  44 527-532
  CrossrefPubMedGoogle Scholar
• 29 Savi P, Combalbert J, Gaich C, Rouchon M-C, Maffrand J P, Berger Y, Herbert J M. The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450 1A.  Thromb Haemost . 1994;  72 313-317
  PubMedGoogle Scholar
• 30 Savi P, Heilmann E, Nurden P. Clopidogrel: an antithrombotic drug acting on the ADP-dependent activation pathway of human platelets.  Clin Appl Thromb/Hemost . 1996;  2 35-42
  PubMedGoogle Scholar
• 31 Savi P, Pereillo J M, Uzabiaga M F. Identification and biological activity of the active metabolite of clopidogrel.  Thromb Haemost . 2000;  84 891-896
  PubMedGoogle Scholar
• 32 Combalbert J, Savi P, Rouchon M C, Berger Y, Herbert J M, Maffrand J P. Influence of hepatic cytochrome P450 subfamilies induction on the microsomal hepatic metabolism and the antiaggregating activity of the thienopyridine clopidogrel (SR25990C). Proceedings of the European Society of Biochemical Pharmacology, Thirteenth European Workshop on Drug Metabolism. Bergamo, Italy: 1992; Sept 21-25
  Google Scholar
• 33 Savi P, Laplace M-C, Maffrand J P, Herbert J M. Binding of ³H-2methylthio-ADP to rat platelets-effect of clopidogrel and ticlopidine.  J Pharmacol Exp Ther . 1994;  269 772-777
  PubMedGoogle Scholar
• 34 Herbert J M, Frehel D, Bernat A. Clopidogrel hydrogenosulfate.  Drug Fut . 1993;  18 107-112
  PubMedGoogle Scholar
• 35 Mills D CB, Puri R, Hu C J. Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase.  Arterioscler Thromb . 1992;  12 430-436
  PubMedGoogle Scholar
• 36 Cattaneo M, Lecchi A, Randi A M, McGregor J L, Mannucci P M. Identification of a new congenital defect of platelet function characterized by severe impairment of platelet responses to adenosine diphosphate.  Blood . 1992;  80 2787-2796
  PubMedGoogle Scholar
• 37 Nurden P, Savi P, Heilmann E, Bihour C, Herbert J M, Maffrand J P, Nurden A. An inherited bleeding disorder linked to a defective interaction between ADP and its receptor on platelets. Its influence on glycoprotein IIb-IIIa complex function.  J Clin Invest . 1995;  95 1612-1622
  PubMedGoogle Scholar
• 38 Savi P, Laplace M C, Herbert J M. Evidence for the existence of two different ADP-binding sites on rat platelets.  Thromb Res . 1994;  76 157-169
  CrossrefPubMedGoogle Scholar
• 39 Gachet C. ADP receptors of platelets and their inhibition.  Thromb Haemost . 2001;  86 222-232
  PubMedGoogle Scholar
• 40 Nicholas R A, Lazarowski E R, Watt W C, Li Q, Boyer J, Harden T K. Pharmacological and second messenger signalling selectivities of cloned P2Y receptors.  J Auton Pharmacol . 1996;  16 319-323
  PubMedGoogle Scholar
• 41 Savi P, Beauverger P, Labouret C, Delfaud M, Salel V, Kaghad M, Herbert J M. Role of P2Y1 purinoceptor in ADP-induced platelet activation.  FEBS Lett . 1998;  422 291-295
  CrossrefPubMedGoogle Scholar
• 42 Leon C, Vial C, Cazenave J P, Gachet C. Cloning and sequencing of a human cDNA encoding endothelial P2Y1 purinoceptor.  Gene . 1996;  171 295-297
  CrossrefPubMedGoogle Scholar
• 43 Jin J, Daniel J L, Kunapuli S P. Molecular basis for ADP-induced platelet activation. II. The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets.  J Biol Chem . 1998;  273 2030-2034
  CrossrefPubMedGoogle Scholar
• 44 Derian C K, Friedman P A. Effects of ticlopidine ex vivo on platelet intracellular calcium mobilization.  Thromb Res . 1988;  50 65-76
  CrossrefPubMedGoogle Scholar
• 45 Fabre J E, Nguyen M, Latour A, Keifer J A, Audoly L P, Coffman T M, Koller B H. Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1-deficient mice.  Nat Med . 1999;  5 1199-1202
  PubMedGoogle Scholar
• 46 Leon C, Hechler B, Freund M. Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y1 receptor-null mice.  J Clin Invest . 1999;  104 1731-1737
  PubMedGoogle Scholar
• 47 Savi P, Bornia J, Salel V, Delfaud M, Herbert J M. Characterization of P2x1 purinoreceptors on rat platelets: effect of clopidogrel.  Br J Haematol . 1997;  98 880-886
  CrossrefPubMedGoogle Scholar
• 48 Vial C, Hechler B, Leon C, Cazenave J P, Gachet C. Presence of P2X1 purinoceptors in human platelets and megakaryoblastic cell lines.  Thromb Haemost . 1997;  78 1500-1504
  PubMedGoogle Scholar
• 49 Oury C, Toth-Zsamboki E, Van Geet C, Nilius B, Vermylen J, Hoylaerts M F. A dominant negative mutation in the platelet P2X1 ADP receptor causes severe bleeding disorder. Important role of P2X1 in ADP-induced platelet aggregation.  Blood . 1999;  (suppl) 618a
  PubMedGoogle Scholar
• 50 Mahaut-Smith M P. ADP is not an agonist at P2X1 receptors: evidence for separate receptors stimulated by ATP and ADP on human platelets.  Br J Pharmacol . 2000;  131 108-114
  CrossrefPubMedGoogle Scholar
• 51 Zhang F L, Luo L, Gustafson E. ADP is the cognate ligand for orphan G-protein coupled receptor SP1999.  J Biol Chem . 2001;  276 8608-8615
  CrossrefPubMedGoogle Scholar
• 52 Hollopeter G, Jantzen H M, Vincent D. Identification of the platelet ADP receptor targeted by antithrombotic drugs.  Nature . 2001;  409 202-207
  CrossrefPubMedGoogle Scholar
• 53 Savi P, Labouret C, Delesque N, Guette F, Lupker J, Herbert J M. P2Y12, a new platelet ADP receptor, target of clopidogrel.  Biochem Biophys Res Commun . 2001;  283 379-383
  CrossrefPubMedGoogle Scholar
• 54 Macfarlane D E, Srivastava P C, Mills D C. 2-Methylthioadenosine [beta-³²P-diphosphate. An agonist and radioligand for the receptor that inhibits the accumulation of cyclic AMP in intact blood platelets.  J Clin Invest . 1983;  71 420-428
  PubMedGoogle Scholar
• 55 Colman R W. Aggregin: a platelet ADP receptor that mediates activation.  FASEB J . 1990;  4 1425-1435
  PubMedGoogle Scholar
• 56 Nandanan E, Jang S Y, Moro S. Synthesis, biological activity, and molecular modeling of ribose-modified deoxyadenosine bisphosphate analogues as P2Y1 receptor ligands.  J Med Chem . 2000;  43 829-842
  CrossrefPubMedGoogle Scholar